HOLX News & Events

Hologic announced that its Aptima HPV Assay received FDA approval for clinician-collected HPV primary screening. Hologic's human papillomavirus test is the only FDA-approved mRNA-based assay, designed specifically to detect infections most likely to lead to cervical cancer.

Reports Q1 revenue $1.05B, consensus $1.07B.

Argus downgraded Hologic (HOLX) to Hold from Buy as the company had agreed in October to be acquired by funds managed by Blackstone (BX) and TPG (TPG) in a transaction valued at up to $79 per share, representing an enterprise value of up to $18.3B. The transaction is expected to close in early February, the analyst tells investors in a research note.